[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","cxy3blkc9nvv0b4lwqri3ad8d","revision",2,"title","Marker Therapeutics 获 FDA 260 万美元孤儿药开发资助","originalTitle","8-K - Marker Therapeutics, Inc. (0001094038) (Filer)","summary","Marker Therapeutics 获 FDA 260 万美元资助，用于推进 MT-601 细胞疗法治疗晚期胰腺癌。该资金来自 FDA 的孤儿药开发计划。MT-601 是公司领先的试验性疗法。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":57,"_93":94,"_95":96},"links",{"_84":85,"_63":86},"publishedAt","2026-10-19T11:12:47.000Z","discoveredAt","2026-10-19T11:17:59.433Z","timelineAt","category","ai-products","tags",[81,82,83],"stockSymbols",[80],"score",45,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fPl0UB449vQw",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","d5cb51a3-0883-4d18-8369-7ab28954387d","Marker Therapeutics 获 FDA 孤儿药资助",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities\nExchange Act of 1934

\nOctober 19, 2026

Date of Report (Date of earliest event reported)

MARKER THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

\n \n \n \n \n \n \n \n \n

Delaware	001-37939	45-4497941
(State or other jurisdiction of \nincorporation)	(Commission File Number)	(IRS Employer Identification No.)

\n \n \n \n \n \n \n \n \n

2450 Holcombe Blvd, TMC Partners Office 1.311

Houston,\n Texas

77021

(Address of principal executive offices)

(Zip Code)

(713) 400-6400

Registrant’s telephone number, including\narea code

(Former name or former address, if changed since\nlast report)

Check the appropriate box below if the Form 8-K is intended to simultaneously\nsatisfy the filing obligation of the registrant under any of the following provisions:

\n \n \n \n \n \n \n \n \n \n \n \n \n

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

\n \n \n \n \n \n \n \n \n \n \n \n \n

Title of each class		Trading \nSymbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		MRKR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities\nExchange Act of 1934 (§240.12b-2 of this chapter).

Emerging\ngrowth company ¨

If an emerging\ngrowth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any\nnew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01.

Other Information

On October19, 2026, Marker Therapeutics, Inc. (“Marker”\nor the “Company”) issued a press release announcing that it was awarded a $2.6 Million Grant by the Food & Drug\nAdministration (“FDA”) under the FDA’s Orphan Products development program to advance the Company’s lead\ninvestigational MAR-T cell therapy, MT-601, in patients with locally advanced unresectable pancreatic cancer.

A copy of the Press Release is attached hereto\nas Exhibit 99.1 and is incorporated by reference herein.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

\n \n \n \n \n \n \n \n \n \n

Exhibit No.	Description
99.1	Press release, dated October 19, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities\nExchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly\nauthorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	Marker Therapeutics, Inc.

Dated: October 19, 2026	By:	/s/ Juan Vera
		Juan Vera
		President and Chief Executive Officer

","zhKind","complete","MRKR","公司与财报","融资","AI","aihot","/items/cxy3blkc9nvv0b4lwqri3ad8d","https://www.sec.gov/Archives/edgar/data/1094038/000110465926116720/0001104659-26-116720-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792627200&sig=564cbec5bb9177d7","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792627200&sig=034656c278a8477b 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792627200&sig=23dae0083a3a8d72 96w","changelogVersion","2026-10-01T08:00"]